Citations

Clear

1526 citation(s) found for "Sun, D".

Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
Nauseef, Jones T. , Thomas, Charlene , Sun, Michael, Jacobs, Nicole , Rüder, S, Fernandez, Escarleth, Davidson, Zachary, Patel, Amie , Vallabhajosula, Shankar , Molina, Ana M. , Nanus, David M. , Castellanos, Sandra Huicochea , Bander, Neil H. , Jacobs, Nicole, Ricaurte‐Fajardo, Andres , Sartor, Oliver , Sternberg, Cora N , Osborne, Joseph R. , Perk, Timothy , Tagawa, Scott T.

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT225-CT225

10.1158/1538-7445.am2024-ct225 Get It

Abstract Background: We have previously reported that 177Lu-PSMA-617 given as a single-cycle, dose-intense regimen for patients (pts) with pretreated mCRPC is efficacious even without selection by PSMA (ESMO 2021). Quantitative analyses of pre-treatment PSMA PET may allow for better patient selection and prediction of toxicities. Analyses of sequential PET images may also provide insights that may be associated with longer term outcomes. Our previous analysis of 13 patients demonstrated association of PSMA PET signal with overall survival (OS) and PSA responses, as well as trends with adverse events (Nauseef GU ASCO 2022). Here we present long-term follow up data and expanded imaging correlatives from our completed phase I/II study. MethodsEntry criteria: progressive mCRPC after at least one prior potent AR pathway inhibitor and prior chemotherapy (excepting men ineligible for or refusing of chemotherapy) with allowance for prior radionuclides (incl. Ra223 and PSMA-TRTs). Treatment was fractionated-dose (D1 and D15) 177Lu-PSMA-617 (7.4-22.2 GBq). TRAQinform IQ (AIQ Solutions) was used to identify, track, and quantify regions of interest suspicious of cancer (lesion-ROI) on PSMA PET/CT images and quantify uptake in normal organs outside of lesion-ROI. Measurements included SUVmean across all lesion-ROI, volume of lesion-ROI, and SUVtotal (sum of SUV in all lesion-ROI), as well as changes after treatment, including in PSMA-expressing healthy tissues. Associations with survival were tested via Cox proportional hazard models in univariate analyses and associations with adverse events (AEs) and PSA responses were via assessed via Wilcoxon rank sum tests. Results32 pts (of 50 total in the study between 1/2017-2/2021) had pre- and post-treatment imaging suitable TRAQinform IQ analysis and associated survival analyses. Baseline characteristics were similar to the entire study cohort. PSA response of 50% was observed in 21/32 (66%) of which 16 were confirmed. No imaging variable predicted PSA30 or PSA50, although an association was observed in pretreatment SUVmean and lesion-ROI volume reduction. No imaging variable was significantly associated with OS (e.g., pretx SUVmean HR 0.9, p=0.10, pretx Volume HR 1.00, p=0.052). Pretx SUVmean was associated with mPFS (HR 0.85, 95% CI 0.74, 0.98, p=0.023). Among select AEs, anemia was associated with non-lesion-ROI skeleton SUVtotal in pre- (p=0.027) and post-tx (p=0.007). Higher pre-treatment salivary gland uptake (SUVmean) was associated with more xerostomia (p=0.11). Fatigue was associated with a variety of variables including salivary SUVs (mean, max, and total) and post-tx bowel SUVmax (p=0.030). ConclusionsPre-treatment and pre- to post-treatment 68Ga-PSMA11-PET data analyzed may be associated with outcome. While a strength of this study is the prospective nature of patient enrollment and fixed imaging timepoints, our associations are limited by small sample size. Expansion of this analysis to larger datasets may improve our ability to predict treatment response and toxicity by body-wide PSMA detection. Citation Format: Jones Trevor Nauseef, Charlene Thomas, Michael Sun, Nicole Jacobs, Andrés Ricaurte Fajardo, Sam Ruder, Escarleth Fernandez, Zachary Davidson, Amie Patel, A. Oliver Sartor, Shankar Vallabhajosula, Ana Molina, Cora N. Sternberg, David M. Nanus, Sandra Huicochea Castellanos, Joseph Osborne, Neil H. Bander, Timothy Perk, Scott Tagawa. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT225.
Rag-GTPase-TFEB/TFE3 axis controls B cell mitochondrial fitness and humoral immunity independent of mTORC1
Zeng, Hu , Zhu, Xingxing , Wu, Yue , Li, Yanfeng , Chen, Yin , Raybuck, Ariel , Billadeau, Daniel D. , Shapiro, Virginia Smith , Zhu, Xingxing , Wu, Y , Watzlawik, Jens O. , Chen, Yin Maggie, Shapiro, Virginia S , Sun, Jie , Zeng, Hu , Zhou, Xian , Springer, Wolfdieter , Sun, Jie , Boothby, Mark Robin

Mayo Clinic

No container title available | March 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3957355/v1 | PMID 38585731 Get It

Abstract During the humoral immune response, B cells undergo rapid metabolic reprogramming with a high demand for nutrients, which are vital to sustain the formation of the germinal centers (GCs). Rag-GTPases sense amino acid availability to modulate the mechanistic target of rapamycin complex 1 (mTORC1) pathway and suppress transcription factor EB (TFEB) and transcription factor enhancer 3 (TFE3), members of the microphthalmia (MiT/TFE) family of HLH-leucine zipper transcription factors. However, how Rag-GTPases coordinate amino acid sensing, mTORC1 activation, and TFEB/TFE3 activity in humoral immunity remains undefined. Here, we show that B cell-intrinsic Rag-GTPases are critical for the development and activation of B cells. RagA/RagB deficient B cells fail to form GCs, produce antibodies, and generate plasmablasts in both T-dependent (TD) and T-independent (TI) humoral immune responses. Deletion of RagA/RagB in GC B cells leads to abnormal dark zone (DZ) to light zone (LZ) ratio and reduced affinity maturation. Mechanistically, the Rag-GTPase complex constrains TFEB/TFE3 activity to prevent mitophagy dysregulation and maintain mitochondrial fitness in B cells, which are independent of canonical mTORC1 activation. TFEB/TFE3 deletion restores B cell development, GC formation in Peyer’s patches and TI humoral immunity, but not TD humoral immunity in the absence of Rag-GTPases. Collectively, our data establish Rag-GTPase-TFEB/TFE3 axis as an mTORC1 independent mechanism to coordinating nutrient sensing and mitochondrial metabolism in B cells.
Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis
Osinga, J. , Liu, Yindi , Vafeiadi, Marina , Tao, Fangbiao , López‐Bermejo, Abel , Boucai, Laura , Hisada, Aya , Yoshinaga, Jun , Broeren, Maarten A.C., Itoh, Sachiko, Kishi, Reiko , Ashoor, Ghalia, Veltri, Flora, Lu, Xuemian , Taylor, Peter , Chatzi, Leda , Grineva, Elena , Ghafoor, Farkhanda, Pirzada, Amna, Kianpour, Maryam , Oken, Emily , Suvanto, Eila, Irizar, Amaia , Boelaert, Kristien , Brenta, Gabriela , Dhillon‐Smith, Rima , Dosiou, Chrysoula , Eaton, Jennifer L., Guan, Haixia , Nguyen, Caroline T. , Pop, Victor J.M. , Walsh, John P. , D’Alton, Mary E. , Carty, David , Delles, Christian , Alexander, Erik K. , Pearce, Elizabeth N. , Derakhshan, Arash , Korevaar, Tim I.M. , Osinga, Joris A J , Boucai, Laura , Feldt-Rasmussen, Ulla , Brenta, Gabriela , Guan, Haixia , Lee, Sun Y , Walsh, John P , Nelson, Scott McGill , Bliddal, Sofie , Pearce, Elizabeth N , Taylor, Peter N , López-Bermejo, Abel , Oken, Emily , Dosiou, Chrysoula , Männistö, Tuija , Vaidya, Bijay , Vrijkotte, Tanja G. M. , Mosso, Lorena , Bassols, Judit , Aminorroaya, Ashraf , Chen, Liangmiao , Brown, Suzanne J , Popova, Polina , Hattersley, Andrew T. , Rebagliato, Marisa , Galán, Isolina Riaño , Vrijheid, Martine , Delgado-Saborit, Juana María , Fernández‐Somoano, Ana , Santa‐Marina, Loreto , Maraka, Spyridoula , Morris, Lilah F. , Shan, Zhongyan , Guxens, Mònica , Nicolaides, Kypros H. , Visser, W. Edward , Nelson, Scott M. , Chaker, Layal , Richards, C. Sue , Peeters, Robin P. , Bliddal, Sofie , Huang, Kun , Poppe, Kris Gustave

Mayo Clinic

Thyroid® | March 28, 2024 | Volume: 34 | Issue: 5 | Pages: 646-658

10.1089/thy.2023.0646 | PMID 38546971 Get It

Background: International guidelines recommend targeted screening to identify gestational thyroid dysfunction. However, currently used risk factors have questionable discriminative ability. We quantified the risk for thyroid function test abnormalities for a subset of risk factors currently used in international guidelines. Methods: We included prospective cohort studies with data on gestational maternal thyroid function and potential risk factors (maternal age, body mass index [BMI], parity, smoking status, pregnancy through in vitro fertilization, twin pregnancy, gestational age, maternal education, and thyroid peroxidase antibody [TPOAb] or thyroglobulin antibody [TgAb] positivity). Exclusion criteria were pre-existing thyroid disease and use of thyroid interfering medication. We analyzed individual participant data using mixed-effects regression models. Primary outcomes were overt and subclinical hypothyroidism and a treatment indication (defined as overt hypothyroidism, subclinical hypothyroidism with thyrotropin >10 mU/L, or subclinical hypothyroidism with TPOAb positivity). Results: The study population comprised 65,559 participants in 25 cohorts. The screening rate in cohorts using risk factors currently recommended (age >30 years, parity ≥2, BMI ≥40) was 58%, with a detection rate for overt and subclinical hypothyroidism of 59%. The absolute risk for overt or subclinical hypothyroidism varied <2% over the full range of age and BMI and for any parity. Receiver operating characteristic curves, fitted using maternal age, BMI, smoking status, parity, and gestational age at blood sampling as explanatory variables, yielded areas under the curve ranging from 0.58 to 0.63 for the primary outcomes. TPOAbs/TgAbs positivity was associated with overt hypothyroidism (approximate risk for antibody negativity 0.1%, isolated TgAb positivity 2.4%, isolated TPOAb positivity 3.8%, combined antibody positivity 7.0%; p < 0.001), subclinical hypothyroidism (risk for antibody negativity 2.2%, isolated TgAb positivity 8.1%, isolated TPOAb positivity 14.2%, combined antibody positivity 20.0%; p < 0.001) and a treatment indication (risk for antibody negativity 0.2%, isolated TgAb positivity 2.2%, isolated TPOAb positivity 3.0%, and combined antibody positivity 5.1%; p < 0.001). Twin pregnancy was associated with a higher risk of overt hyperthyroidism (5.6% vs. 0.7%; p < 0.001). Conclusions: The risk factors assessed in this study had poor predictive ability for detecting thyroid function test abnormalities, questioning their clinical usability for targeted screening. As expected, TPOAb positivity (used as a benchmark) was a relevant risk factor for (subclinical) hypothyroidism. These results provide insights into different risk factors for gestational thyroid dysfunction.
Abstract 4959: Immunopipe: A comprehensive and flexible scRNA-seq and scTCR-seq data analysis pipeline
Wang, Panwen , Yu, Yue , Kocher, Jean-Pierre A., Lin, Yi, Li, Ying , Dong, Haidong , Yu, Yue, Zhang, Shuwen , Sun, Zhifu , Wang, Junwen

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 4959-4959

10.1158/1538-7445.am2024-4959 Get It

Abstract Introduction: Single-cell RNA-sequencing (scRNA-seq) pairing with single-cell T-Cell-Receptor-sequencing (scTCR-seq) enables profiling of gene expression and TCR repertoires in individual T cells, elevating our understanding of T-cell-mediated immunity. Here, we present immunopipe, a comprehensive and flexible pipeline (https://github.com/pwwang/immunopipe) for analyzing the paired data. Besides the command-line tool, it offers a user-friendly web interface that allows users with varying programming expertise to configure, initiate, and monitor the pipeline. By combining extensive functionality with ease of use, immunopipe empowers users to unlock valuable insights from the data, which notably advances our understanding of immune response and fosters the development of innovative immunotherapies. Results: Immunopipe is a comprehensive analytical pipeline for scRNA-seq and scTCR-seq data, offering various modules leveraging existing tools and novel methods to ensure data quality and enable downstream analytics. It performs quality control for scRNA-seq data, clusters cells based on gene expression to facilitate the identification of cell populations and provides insights into T-cell heterogeneity and functional diversity through T-cell selection and clustering. Enrichment analysis identifies markers and pathways for T-cell characterization. Our automated T-cell annotation tool annotates cell types accurately and hierarchically. For scTCR-seq data, immunopipe analyzes TCR clones, including clonality, diversity, gene usage, and repertoire overlap. Clone residency analysis examines the presence of clones across samples. Integrative analyses combine scRNA-seq and scTCR-seq data, providing a comprehensive understanding of the cellular landscape. Immunopipe incorporates diverse cell group information to analyze T-cell populations, which enables granular perspectives of the data for comprehensive insights. Immunopipe offers a flexible platform, allowing users to customize the analyses as needed. It supports both core and optional analyses through configuration, where users have control over the adjustable parameters. The pipeline relies on cell grouping information that can be referenced from metadata or modified to generate new variables for analysis and data filtering. Immunopipe can be executed locally or on scheduler platforms, and a docker image is provided for compatibility and simplified installation. It also offers a web interface that facilitates configuration, execution monitoring, and access to results. Conclusion: Immunopipe is a flexible and user-friendly pipeline for analyzing scRNA-seq and scTCR-seq data. It empowers researchers to gain valuable insights that could enhance the understanding of immune responses and facilitate the development of innovative immunotherapies. Citation Format: Panwen Wang, Haidong Dong, Yue Yu, Shuwen Zhang, Zhifu Sun, Jean-Pierre A. Kocher, Junwen Wang, Lin Yi, Ying Li. Immunopipe: A comprehensive and flexible scRNA-seq and scTCR-seq data analysis pipeline [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4959.
Abstract 2424: Detection of prostate cancer in urine by fragment-level DNA methylation analysis
Baheti, Saurabh , Cao, Xiaoming , Burger, Kelli N. , Gochanour, Benjamin R. , Douglas, Wayne, Gettman, Matthew T., Bedekovics, Tibor , Taylor, William R. , Sun, Zhifu , Doering, Karen A. , Foote, Patrick H. , Mahoney, Douglas, W., Kisiel, John B.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 2424-2424

10.1158/1538-7445.am2024-2424 Get It

Abstract Introduction: Screening for prostate cancer (PCa) with molecular markers is hindered by low tumor allele fraction (TAF) in liquid biopsy samples such as blood or urine. Others have suggested that tumor allele enrichment can be achieved by evaluating fragment-level methylation patterns generated by next generation sequencing (NGS). Here, we test this concept using target capture NGS on cfDNA from prediagnostic collected urine samples to discriminate PCa from otherwise healthy men. Methods: Buffered urines were collected from 23 patients with biopsy confirmed PCa (Gleason score 6-9) and 24 otherwise healthy age matched cancer-free controls. cfDNA was isolated and enzymatic methyl-seq libraries were prepared and enriched by hybrid capture using probes mapping to 197 differentially methylated regions (DMRs) from a previous PCa/normal tissue marker discovery study in our lab. These DMRs were subsequently vetted independently using a methylome-wide dataset from a cohort of 36 clean and disease control urines to ensure low non-cancer background signal (&lt;1%). Indexed libraries were sequenced at 560X deduplicated coverage and fragment-level CpG methylation information was extracted from individual sample .bam files. Mapped sequencing reads exhibiting concordant methylation were used to derive a quantitative α-score. Reads had to contain at minimum 5 CpGs and have an α-value (% 5mC per read) &gt; 60%. Positivity for the 197 markers required an α-score greater than 6 sigma (σ) above the mean of the control arm. Values were variance-adjusted to ensure equal weighting. Beta (β) analysis (mean % 5mC across all reads) of the data was also performed for comparison. Results: Of the 197 markers, 187 were positive for one or more PCa patients. Tumor-derived fragments were detected in 22 of 23 cases, which included 8 G-6, 9 G-7, 2 G-8, and 3 G-9 patients. 1 G-7 was missed, however the sequencing coverage for this sample was significantly lower than the others due to poor library enrichment. 2 of the 24 healthy controls were positive, one with extremely high fragment counts. Upon re-review of the full control cohort, this patient had been diagnosed with bladder cancer 2 years after urine collection. The 2nd patient had was diagnosed with lung cancer in a similar timeframe. The other 22 confirmed cancer-free controls had α-scores below the 6σ threshold. Using a co-captured reference gene (B3GALT6) to mimic genomic equivalents, the TAFs ranged from 0.015% to 8%. β analysis of the data detected only 13 PCa patients (&gt;6σ) and marker positivity was lower than the fragment-level approach. Conclusion: Target capture NGS coupled with fragment-level analysis is a rational approach for sensitive and specific detection of low tumor-derived DNA in liquid biopsy samples. For PCa assay in urine, we were able to uncover positivity in cancer patients approaching 1 in 10,000 ctDNA dilution levels. These results warrant further validation studies with this and other cancers. Citation Format: Tibor Bedekovics, William R. Taylor, Zhifu Sun, Saurabh Baheti, Xiaoming Cao, Kelli N. Burger, Karen A. Doering, Patrick H. Foote, Benjamin Gochanour, Douglas, W. Mahoney, Matthew T. Gettman, John B. Kisiel. Detection of prostate cancer in urine by fragment-level DNA methylation analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2424.
IL-8+ neutrophils drive inexorable inflammation in severe alcohol-associated hepatitis
Guan, Yukun , Peiffer, Brandon , Feng, Dechun , Parra, Maria A. , Wang, Yang , Fu, Yaojie , Shah, Vijay H. , Cameron, Andrew M. , Sun, Zhaoli , Peiffer, Brandon , Gao, Bin

Mayo Clinic

Journal of Clinical Investigation | March 19, 2024 | Volume: 134 | Issue: 9 | Pages: No page available

10.1172/jci178616 | PMID 38502218 Get It

Managing high blood sugar (hyperglycemia) during pasireotide treatment: A plain language summary of the B2219 study
Samson, Susan L. , Zhang, Shao‐Ling , Yu, Yerong , Feldt-Rasmussen, Ulla , Witek, Przemysław , Kalra, Pramila , Bolanowski, Marek

Mayo Clinic

Future Rare Diseases | March 19, 2024 | Volume: 4 | Issue: 1 | Pages: No page available

10.2217/frd-2023-0025 Get It

Utilizing Linear Logistic Test Models to Explore Item Characteristics of Medical Subspecialty Certification Examinations
Toutkoushian, Emily , Sun, Huaping , Keegan, Mark T. , Harman, Ann E., Sun, Huaping

Mayo Clinic

Measurement: Interdisciplinary Research and Perspectives | March 5, 2024 | Volume: 22 | Issue: 4 | Pages: 420-434

10.1080/15366367.2023.2273581 Get It

Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Møller, Pål , McCuaig, Jeanna , Eisen, Andrea , Bordeleau, Louise , Zakalik, Dana , Metcalfe, Kelly , Olopade, Olufunmilayo I. , Sun, Ping , Narod, Steven A. , Sweet, Kevin , Elser, Christine , Wiesner, Georgia L. , Poll, Aletta, Kim, Raymond H. , Armel, Susan T., Demsky, Rochelle, Serfas, Kim, Panchal, Seema, Cullinane, Carey A., Reilly, Robert E., Mercer, L J, Dungan, J.S., Lemire, Edmond G., Zovato, Stefania , Rastelli, Antonella, Olopade, Olufunmilayo I , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Kotsopoulos, Joanne , Gronwald, Jacek , Huzarski, Tomasz , Pal, Tuya , Singer, Christian F. , Karlan, Beth Y. , Aeilts, Amber M. , Eng, Charis , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Fruscio, Robert , Neuhausen, Susan L. , Cybulski, Cezary , Lubiński, Jan , Armel, Susan, Steele, Linda, Saal, Howard M. , Rayson, Daniel , Mercer, Leanne, Cajal, Teresa Ramón y , Cohen, Stephanie A.

Mayo Clinic

JAMA Oncology | February 29, 2024 | Volume: 10 | Issue: 4 | Pages: 484

10.1001/jamaoncol.2023.6937 | PMID 38421677 Get It

ImportancePreventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2; however, the association of oophorectomy with all-cause mortality has not been clearly defined.ObjectiveTo evaluate the association between bilateral oophorectomy and all-cause mortality among women with a BRCA1 or BRCA2 sequence variation.Design, Setting, and ParticipantsIn this international, longitudinal cohort study of women with BRCA sequence variations, information on bilateral oophorectomy was obtained via biennial questionnaire. Participants were women with a BRCA1 or BRCA2 sequence variation, no prior history of cancer, and at least 1 follow-up questionnaire completed. Women were followed up from age 35 to 75 years for incident cancers and deaths. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) and 95% CIs for all-cause mortality associated with a bilateral oophorectomy (time dependent). Data analysis was performed from January 1 to June 1, 2023.ExposuresSelf-reported bilateral oophorectomy (with or without salpingectomy).Main Outcomes and MeasuresAll-cause mortality, breast cancer–specific mortality, and ovarian cancer–specific mortality.ResultsThere were 4332 women (mean age, 42.6 years) enrolled in the cohort, of whom 2932 (67.8%) chose to undergo a preventive oophorectomy at a mean (range) age of 45.4 (23.0-77.0) years. After a mean follow-up of 9.0 years, 851 women had developed cancer and 228 had died; 57 died of ovarian or fallopian tube cancer, 58 died of breast cancer, 16 died of peritoneal cancer, and 97 died of other causes. The age-adjusted HR for all-cause mortality associated with oophorectomy was 0.32 (95% CI, 0.24-0.42; P &amp;lt; .001). The age-adjusted HR was 0.28 (95% CI, 0.20-0.38; P &amp;lt; .001) and 0.43 (95% CI, 0.22-0.90; P = .03) for women with BRCA1 and BRCA2 sequence variations, respectively. For women with BRCA1 sequence variations, the estimated cumulative all-cause mortality to age 75 years for women who had an oophorectomy at age 35 years was 25%, compared to 62% for women who did not have an oophorectomy. For women with BRCA2 sequence variations, the estimated cumulative all-cause mortality to age 75 years was 14% for women who had an oophorectomy at age 35 years compared to 28% for women who did not have an oophorectomy.Conclusions and RelevanceIn this cohort study among women with a BRCA1 or BRCA2 sequence variation, oophorectomy was associated with a significant reduction in all-cause mortality.
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Møller, Pål , Eisen, Andrea , Peck, Larissa , Bordeleau, Louise , Zakalik, Dana , Stempa, Klaudia , Dungan, J.S., Cullinane, Carey A., Olopade, Olufunmilayo I. , Metcalfe, Kelly , Sun, Ping , Narod, Steven A. , Sweet, Kevin , Velsher, Lea, McCuaig, Jeanna , Panchal, Seema, Poll, Aletta, Lemire, Edmond G., Serfas, Kim, Costalas, Josephine Wagner, Blum, Joanne L. , Olopade, Olufunmilayo I , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Lubiński, Jan , Kotsopoulos, Joanne , Pal, Tuya , Karlan, Beth Y. , Aeilts, Amber M. , Eng, Charis , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Fruscio, Robert , Cajal, Teresa Ramón y , Singer, Christian F. , Neuhausen, Susan L. , Cybulski, Cezary , Gronwald, Jacek , Huzarski, Tomasz , Senter, Leigha , Saal, Howard M. , Armel, Susan Randall , Reilly, Richard B. , Cohen, Stephanie A.

Mayo Clinic

JAMA Oncology | February 29, 2024 | Volume: 10 | Issue: 4 | Pages: 493

10.1001/jamaoncol.2023.6944 | PMID 38421676 Get It

Importance Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast cancers, but the association of MRI surveillance with mortality risk has not been well defined. Objective To compare breast cancer mortality rates in women with a BRCA1 or BRCA2 sequence variation who entered an MRI surveillance program with those who did not. Design, Setting, and Participants Women with a BRCA1 or BRCA2 sequence variation were identified from 59 participating centers in 11 countries. Participants completed a baseline questionnaire between 1995 and 2015 and a follow-up questionnaire every 2 years to document screening histories, incident cancers, and vital status. Women who had breast cancer, a screening MRI examination, or bilateral mastectomy prior to enrollment were excluded. Participants were followed up from age 30 years (or the date of the baseline questionnaire, whichever was later) until age 75 years, the last follow-up, or death from breast cancer. Data were analyzed from January 1 to July 31, 2023. Exposures Entrance into an MRI surveillance program. Main Outcomes and Measures Cox proportional hazards modeling was used to estimate the hazard ratios (HRs) and 95% CIs for breast cancer mortality associated with MRI surveillance compared with no MRI surveillance using a time-dependent analysis. Results A total of 2488 women (mean [range] age at study entry 41.2 [30-69] years), with a sequence variation in the BRCA1 (n = 2004) or BRCA2 (n = 484) genes were included in the analysis. Of these participants, 1756 (70.6%) had at least 1 screening MRI examination and 732 women (29.4%) did not. After a mean follow-up of 9.2 years, 344 women (13.8%) developed breast cancer and 35 women (1.4%) died of breast cancer. The age-adjusted HRs for breast cancer mortality associated with entering an MRI surveillance program were 0.20 (95% CI, 0.10-0.43; P &amp;lt; .001) for women with BRCA1 sequence variations and 0.87 (95% CI, 0.10-17.25; P = .93) for women with BRCA2 sequence variations. Conclusion and Relevance Results of this cohort study suggest that among women with a BRCA1 sequence variation, MRI surveillance was associated with a significant reduction in breast cancer mortality compared with no MRI surveillance. Further studies of women with BRCA2 sequence variations are needed to ascertain these women obtain the same benefits associated with MRI surveillance.